Drugs / IM19 CAR-T
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03344705 | Aug 2017 → Oct 2020 | hematopoietic and lymphoid cell neoplasm | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03173417 | May 2017 → May 2019 | leukemia | Beijing Immunochina Medical Science & Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03142646 | Aug 2016 → Jun 2018 | leukemia | Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IM19CART | “A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.” NCT03142646 ↗ |
| Modality | Cell therapy | “T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor” NCT03142646 ↗ |
| Route | Intravenous | “single infusion of IM19CART cells administered intravenously” NCT03142646 ↗ |
| Target | CD19 | “Anti-CD19 Chimeric Antigen Receptor” NCT03142646 ↗ |